Savara (SVRA) to Release Earnings on Tuesday

Savara (NASDAQ:SVRA) will likely be posting its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect Savara to post earnings of ($0.12) per share for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 13, 2026 at 7:00 AM ET.

Savara (NASDAQ:SVRA) last issued its earnings results on Friday, March 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). On average, analysts expect Savara to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Savara Trading Up 2.4%

Shares of NASDAQ:SVRA opened at $5.08 on Tuesday. Savara has a 52-week low of $1.89 and a 52-week high of $7.01. The company has a debt-to-equity ratio of 0.15, a quick ratio of 11.85 and a current ratio of 11.85. The company has a market capitalization of $1.04 billion, a P/E ratio of -9.58 and a beta of 0.31. The company has a 50-day simple moving average of $5.59 and a 200 day simple moving average of $5.04.

Institutional Investors Weigh In On Savara

A number of large investors have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. increased its stake in Savara by 6.9% during the 4th quarter. Osaic Holdings Inc. now owns 32,678 shares of the company’s stock worth $197,000 after acquiring an additional 2,098 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Savara by 3.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 69,536 shares of the company’s stock worth $420,000 after purchasing an additional 2,116 shares in the last quarter. Graham Capital Management L.P. grew its holdings in shares of Savara by 4.9% during the 4th quarter. Graham Capital Management L.P. now owns 56,013 shares of the company’s stock worth $338,000 after purchasing an additional 2,615 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Savara by 52.3% in the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after purchasing an additional 4,626 shares during the period. Finally, The Manufacturers Life Insurance Company increased its position in shares of Savara by 13.2% in the fourth quarter. The Manufacturers Life Insurance Company now owns 43,547 shares of the company’s stock worth $263,000 after purchasing an additional 5,080 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on SVRA shares. Wall Street Zen lowered Savara from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Oppenheimer set a $10.00 target price on Savara in a research note on Tuesday, December 23rd. Guggenheim reissued a “buy” rating on shares of Savara in a report on Tuesday, December 23rd. William Blair set a $10.00 price target on Savara in a research note on Monday, March 16th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Savara in a report on Monday, March 16th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $9.00.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.